http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-017202-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-435 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4188 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-54 |
| filingDate | 1998-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-017202-A1 |
| titleOfInvention | ORAL PHARMACEUTICAL DOSAGE FORM OF PULSED RELEASE AND PROCEDURE FOR THE PREPARATION OF THE SAME AND ITS USE FOR THE MANUFACTURE OF A MEDICINE |
| abstract | An enteric coating pharmaceutical dosage form comprising an H + inhibitor, K + -ATPase. The dosage form comprises at least two portions of the H + inhibitor, K + -ATPase to be released in at least two consecutive pulses. The dosage form has at least one fraction with a pulsed delayed release and another fraction with an instant release of the H + inhibitor, K + -ATPase. The portions are released over time at intervals of from 0.5 and up to 12 hours, preferably from intervals of 0.5 and up to 8 hours, and even more preferably at intervals of from 0.5 and up to 4 hours. The dosage form is intended for administration once a day, and the H +, K + -ATPase inhibitor is a compound of formula (I), an alkaline salt of compound (I), an enantiomer of compound (I) or a salt alkaline unenantiomer of compound (I). Formula (I), where Het1 is formula (II), Het2 is formula (III); X = formula (IV), where N in the benzimidaz portion means that one of the ring carbon atoms substituted by R6-R9 may be optionally exchanged for a nitrogen atom without any substituent; R1, R2 and R3 are the same or different and are selected from hydrogen, alkyl, alkoxy, optionally substituted with fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy; R4 and R5 are the same or different and are selected from hydrogen, alkyl and arylalkyl; R6 is hydrogen, halogen, trifluoromethyl, alkyl or alkoxy; R6 and R9 are the same or different and are selected from hydrogen, alkyl, alkoxy, halogen, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolinyl and trifluoralkyl, or adjacent R6-R9 groups form ring structures that may be further substituted; R10 is hydrogen or forms an alkylene chain together with R3 and R11 and R12 are the same or different and are selected from hydrogen, halogen or alkyl. In addition a tablet or granule in layer for the dosage form, a process for the preparation |
| priorityDate | 1997-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.